Anhui WSD Pharmaceutical Co., Ltd. announces that it has obtained the CDE registration number for Hydrocortisone Sodium Succinate, representing a key regulatory milestone for the company.
Hydrocortisone Sodium Succinate is a water-soluble corticosteroid commonly used in injectable formulations for clinical applications requiring rapid corticosteroid activity. It is included in treatment regimens for inflammatory and allergic conditions, adrenal insufficiency, shock, and other indications under medical supervision. The product is valued for its fast onset and suitability for emergency and hospital use.
The successful registration reflects Anhui WSD Pharmaceutical's capabilities in regulatory compliance and dossier preparation. With solid experience in import registration, regulatory coordination, and pharmaceutical export, the company supports global partners with compliant products and reliable supply services.
Anhui WSD Pharmaceutical will continue to expand its regulated product portfolio and strengthen cooperation with international partners.
